Anti cd3 monoclonal antibody    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
97Ulcerative colitis6

97. Ulcerative colitis    [ 2,269 clinical trials,   1,331 drugs,   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways]
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 2,269 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-004105-28-FR
(EUCTR)
26/04/200723/02/2007An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ SAn Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ S Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
MedDRA version: 9.0;Level: LLT;Classification code 10045365
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti CD3 monoclonal antibody
PDL BioPharma, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
300Hungary;Germany;United Kingdom;Netherlands;France;Ireland;Greece
2EUCTR2005-004105-28-GR
(EUCTR)
15/03/200715/02/2007An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ SAn Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ S Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
MedDRA version: 9.0;Level: LLT;Classification code 10045365
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti CD3 monoclonal antibody
PDL BioPharma, Inc.NULLNot RecruitingFemale: yes
Male: yes
300Hungary;Germany;United Kingdom;Netherlands;France;Ireland;Greece
3EUCTR2005-004105-28-DE
(EUCTR)
11/10/200610/04/2006An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ SAn Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ S Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
MedDRA version: 9.0;Level: LLT;Classification code 10045365
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti CD3 monoclonal antibody
PDL BioPharma, Inc.NULLNot RecruitingFemale: yes
Male: yes
300Hungary;United Kingdom;Germany;Netherlands;France;Ireland;Greece
4EUCTR2005-004105-28-NL
(EUCTR)
28/09/200610/08/2006An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative ColitisAn Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
MedDRA version: 9.0;Level: LLT;Classification code 10045365
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti CD3 monoclonal antibody
PDL BioPharma, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
300Hungary;Germany;United Kingdom;Netherlands;France;Ireland;Greece
5EUCTR2005-004105-28-IE
(EUCTR)
20/06/200610/02/2006An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis.An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis. Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC).
MedDRA version: 8.0;Level: LLT;Classification code 10045265
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti CD3 monoclonal antibody
PDL BioPharma, Inc.NULLNot RecruitingFemale: yes
Male: yes
300Phase 2France;Hungary;Greece;Ireland;Netherlands;Germany;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2005-004105-28-GB
(EUCTR)
20/06/200607/03/2006An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis.An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis. Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC).
MedDRA version: 8.0;Level: LLT;Classification code 10045265
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti CD3 monoclonal antibody
PDL BioPharma, Inc.NULLNot RecruitingFemale: yes
Male: yes
300Hungary;Germany;United Kingdom;Netherlands;France;Ireland;Greece